+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhalational anaesthetics in the ICU: theory and practice of inhalational sedation in the ICU, economics, risk-benefit



Inhalational anaesthetics in the ICU: theory and practice of inhalational sedation in the ICU, economics, risk-benefit



Best Practice and Research. Clinical Anaesthesiology 19(3): 523-538



ICU sedation poses many problems. The action and side-effects of intravenous drugs in the severely ill patient population of an ICU are difficult to control. The incidence of post-traumatic stress disorder after long-term sedation is high. The recent focus on propofol infusion syndrome entails restrictions in the use of this drug. On the other hand, volatile anaesthetics very selectively suppress consciousness but leave many autonomic functions intact. In the absence of perception and disturbed information processing the number of adverse experiences should be lower, leading to a better psychological outcome. Respiration and intestinal motility are not depressed, facilitating modern therapeutic concepts such as early enteral feeding and augmentation of spontaneous breathing. Awakening after inhalational ICU sedation is quick and predictable, extubation can be planned and organized, and the time during which the patient needs very close observation will be short. Technological advances have greatly simplified the application of inhalational anaesthetics. New anaesthesia ventilators offer ventilatory modes and high flow generation comparable to ICU ventilators. However, they are not yet licensed for stand-alone use. The introduction of a volatile anaesthetic reflection filter for the first time enables the concept of inhalational sedation to be performed with very little effort by many ICUs. This 'anaesthetic conserving device' (AnaConDa) is connected between the patient and a normal ICU ventilator, and it retains 90% of the volatile anaesthetic inside the patient just like a heat and moisture exchanger. In this chapter possible advantages of the new concept and the choice of the inhalational agent are discussed. The technical prerequisites are explained, and the practice and pitfalls of inhalational ICU sedation in general and when using the AnaConDa are described in detail.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049356381

Download citation: RISBibTeXText

PMID: 16013698

DOI: 10.1016/j.bpa.2005.02.006


Related references

A review of the practice of sedation with inhalational anaesthetics in the intensive care unit with the AnaConDa(®) device. Indian Journal of Anaesthesia 56(6): 518-523, 2012

Inhalational anaesthetics. 2012

Inhalational anaesthetics. Anaesthesia & Intensive Care Medicine 9(12): 567-572, 2008

Inhalational anaesthetics. Anaesthesia & Intensive Care Medicine 16(12): 641-646, 2015

New inhalational anaesthetics. Anaesthesist 45(8): 674-693, 1996

Update on inhalational anaesthetics. Current Opinion in Anaesthesiology 22(4): 491-495, 2009

Halogenated inhalational anaesthetics. Best Practice and Research. Clinical Anaesthesiology 17(1): 29-46, 2003

Inhalational anaesthetics in neurosurgery. Current Opinion in Anaesthesiology 7(5): 421-425, 1994

Pharmacokinetics of Inhalational Anaesthetics. Lancet 2(7351): 143-145, 1964

The newer inhalational anaesthetics. Practitioner 161(965): 361-371, 1948

Hepatotoxicity of inhalational anaesthetics. Current Opinion in Anaesthesiology 2(4): 414-417???417, 1989

Inhalational anaesthetics and cardioprotection. Handbook of Experimental Pharmacology 2008(182): 187-207, 2008

Inhalational anaesthetics: an update. Acta Anaesthesiologica Belgica 47(1): 3-6, 1996

Inhalational sedation with isoflurane: an alternative to nitrous oxide sedation in dentistry. British Dental Journal 163(3): 88-92, 1987

No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001. Clinical Infectious Diseases 41(7): 991-997, 2005